Please provide your email address to receive an email when new articles are posted on . As the combination of bumetanide and chlorthalidone reduced arterial pressure and volume overload in patients ...

Tirzepatide significantly reduces cardiovascular death or worsening heart failure risk by 38% in patients with obesity-related HFpEF. The drug improves blood pressure, inflammation, and volume ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and fluid overload are at risk for cardiovascular events and kidney disease ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...